Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the obese population is highly underserved. The inability of patients to maintain weight loss with currently available therapies drives the demand for agents that can help sustain long-term weight control, according to a new Pharmacor study from Decision Resources entitled Obesity.

"Because weight-loss therapies are not reimbursed by third-party payers in most major markets, the out-of-pocket expense for the two leading weight-loss therapies -- orlistat (Roche's Xenical) and sibutramine (Abbott/Knoll's Meridia, AstraZeneca/Eisai's Reductil) -- is costly for patients. Physicians report that this expense is a major reason for noncompliance and discontinuation of therapy among their obese patients," said Carole Gleeson, analyst at Decision Resources. "The lackluster performance of currently marketed drugs creates vast commercial opportunities in the obesity market."

About Obesity

Obesity is a major risk factor for several chronic conditions including cardiovascular disease and type 2 diabetes. The prevalence of obesity has increased to epidemic proportions in the United States and Europe. Although the prevalent population of overweight and obese people exceeds 286 million, the market for antiobesity drugs in the United States, Europe, and Japan totaled only $520 million in 2002. However, the increasing prevalence of overweight and obesity and the launch of new agents will expand this market to $1.6 billion by 2012.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Obesity is a Metabolic Disorders study.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for more than 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.DecisionResources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Social Anxiety Disorder Market to Triple Sales Volume by 2012

View Now